Efficacy and safety of S‐1 monotherapy in previously treated elderly patients (aged ≥75 years) with non‐small cell lung cancer: A retrospective analysis
Background S‐1 monotherapy is effective and feasible for previously treated patients with advanced non‐small cell lung cancer (NSCLC). However, it is not clear whether its effectiveness and tolerability in elderly patients are equivalent to those in younger patients. Hence, this study aimed to evalu...
Main Authors: | , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-10-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.13622 |
id |
doaj-7e198e7561bd474cb890ba2ea661d46d |
---|---|
record_format |
Article |
spelling |
doaj-7e198e7561bd474cb890ba2ea661d46d2020-11-25T03:35:30ZengWileyThoracic Cancer1759-77061759-77142020-10-0111102867287610.1111/1759-7714.13622Efficacy and safety of S‐1 monotherapy in previously treated elderly patients (aged ≥75 years) with non‐small cell lung cancer: A retrospective analysisHisao Imai0Hiroyuki Minemura1Takayuki Kishikawa2Yutaka Yamada3Kensuke Suzuki4Yukihiro Umeda5Satoshi Wasamoto6Norimitsu Kasahara7Shinichi Ishihara8Ou Yamaguchi9Ichiro Naruse10Junji Uchino11Keita Mori12Kenya Kanazawa13Yoko Shibata14Takashi Kasai15Takayuki Kaburagi16Kyoichi Kaira17Koichi Minato18Division of Respiratory Medicine Gunma Prefectural Cancer Center Ota JapanDepartment of Pulmonary Medicine Fukushima Medical University Fukushima JapanDivision of Thoracic Oncology Tochigi Cancer Center Utsunomiya JapanDivision of Respiratory Medicine Ibaraki Prefectural Central Hospital Kasama JapanDivision of Internal Medicine Toyama Prefectural Central Hospital Toyama JapanThird Department of Internal Medicine Faculty of Medical Sciences, University of Fukui Eiheiji JapanDivision of Respiratory Medicine Saku Central Hospital Advanced Care Center Saku JapanInnovative medical research center Gunma University Hospital Maebashi JapanDepartment of Internal Medicine Isesaki Municipal Hospital Isesaki JapanDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center Saitama Medical University Hidaka JapanDivision of Respiratory Medicine Hidaka Hospital Takasaki JapanDepartment of Pulmonary Medicine Kyoto Prefectural University of Medicine Kyoto JapanClinical Research Promotion Unit Clinical Research Center, Shizuoka Cancer Center Nagaizumi JapanDepartment of Pulmonary Medicine Fukushima Medical University Fukushima JapanDepartment of Pulmonary Medicine Fukushima Medical University Fukushima JapanDivision of Thoracic Oncology Tochigi Cancer Center Utsunomiya JapanDivision of Respiratory Medicine Ibaraki Prefectural Central Hospital Kasama JapanDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center Saitama Medical University Hidaka JapanDivision of Respiratory Medicine Gunma Prefectural Cancer Center Ota JapanBackground S‐1 monotherapy is effective and feasible for previously treated patients with advanced non‐small cell lung cancer (NSCLC). However, it is not clear whether its effectiveness and tolerability in elderly patients are equivalent to those in younger patients. Hence, this study aimed to evaluate the efficacy and feasibility of S‐1 monotherapy in elderly patients with NSCLC who had previously received other treatments. Methods We included 96 elderly patients (aged ≥75 years) with advanced NSCLC treated with S‐1 alone as a subsequent‐line treatment at 12 medical facilities between January 2005 and March 2018 in this study. The baseline characteristics of the patients, response to S‐1 monotherapy, and adverse events (AEs) were investigated, retrospectively. Results A total of 68 male and 28 female patients (median age, 78 [range: 75–86] years) were analyzed. In elderly patients who were treated with S‐1 monotherapy as a subsequent‐line treatment, the objective response rate, disease control rate, median progression‐free survival (PFS), and overall survival (OS) were 8.3%, 43.8%, 3.4 months, and 9.6 months, respectively. Observed AEs included anorexia, anemia, nausea, fatigue, reduced platelet count, and skin hyperpigmentation. Treatment‐related death was observed in one patient because of pneumonitis. In patients who experienced no progressive disease, subsequent‐line S‐1 alone was associated with longer PFS and OS. Conclusions S‐1 monotherapy is effective and feasible as a subsequent‐line treatment in elderly patients who were previously treated for NSCLC, and it produces results. S‐1 monotherapy could be one of the treatment choices for elderly patients with previously treated NSCLC.https://doi.org/10.1111/1759-7714.13622Advanced non‐small cell lung cancerelderly patientsS‐1 monotherapysubsequent‐line therapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hisao Imai Hiroyuki Minemura Takayuki Kishikawa Yutaka Yamada Kensuke Suzuki Yukihiro Umeda Satoshi Wasamoto Norimitsu Kasahara Shinichi Ishihara Ou Yamaguchi Ichiro Naruse Junji Uchino Keita Mori Kenya Kanazawa Yoko Shibata Takashi Kasai Takayuki Kaburagi Kyoichi Kaira Koichi Minato |
spellingShingle |
Hisao Imai Hiroyuki Minemura Takayuki Kishikawa Yutaka Yamada Kensuke Suzuki Yukihiro Umeda Satoshi Wasamoto Norimitsu Kasahara Shinichi Ishihara Ou Yamaguchi Ichiro Naruse Junji Uchino Keita Mori Kenya Kanazawa Yoko Shibata Takashi Kasai Takayuki Kaburagi Kyoichi Kaira Koichi Minato Efficacy and safety of S‐1 monotherapy in previously treated elderly patients (aged ≥75 years) with non‐small cell lung cancer: A retrospective analysis Thoracic Cancer Advanced non‐small cell lung cancer elderly patients S‐1 monotherapy subsequent‐line therapy |
author_facet |
Hisao Imai Hiroyuki Minemura Takayuki Kishikawa Yutaka Yamada Kensuke Suzuki Yukihiro Umeda Satoshi Wasamoto Norimitsu Kasahara Shinichi Ishihara Ou Yamaguchi Ichiro Naruse Junji Uchino Keita Mori Kenya Kanazawa Yoko Shibata Takashi Kasai Takayuki Kaburagi Kyoichi Kaira Koichi Minato |
author_sort |
Hisao Imai |
title |
Efficacy and safety of S‐1 monotherapy in previously treated elderly patients (aged ≥75 years) with non‐small cell lung cancer: A retrospective analysis |
title_short |
Efficacy and safety of S‐1 monotherapy in previously treated elderly patients (aged ≥75 years) with non‐small cell lung cancer: A retrospective analysis |
title_full |
Efficacy and safety of S‐1 monotherapy in previously treated elderly patients (aged ≥75 years) with non‐small cell lung cancer: A retrospective analysis |
title_fullStr |
Efficacy and safety of S‐1 monotherapy in previously treated elderly patients (aged ≥75 years) with non‐small cell lung cancer: A retrospective analysis |
title_full_unstemmed |
Efficacy and safety of S‐1 monotherapy in previously treated elderly patients (aged ≥75 years) with non‐small cell lung cancer: A retrospective analysis |
title_sort |
efficacy and safety of s‐1 monotherapy in previously treated elderly patients (aged ≥75 years) with non‐small cell lung cancer: a retrospective analysis |
publisher |
Wiley |
series |
Thoracic Cancer |
issn |
1759-7706 1759-7714 |
publishDate |
2020-10-01 |
description |
Background S‐1 monotherapy is effective and feasible for previously treated patients with advanced non‐small cell lung cancer (NSCLC). However, it is not clear whether its effectiveness and tolerability in elderly patients are equivalent to those in younger patients. Hence, this study aimed to evaluate the efficacy and feasibility of S‐1 monotherapy in elderly patients with NSCLC who had previously received other treatments. Methods We included 96 elderly patients (aged ≥75 years) with advanced NSCLC treated with S‐1 alone as a subsequent‐line treatment at 12 medical facilities between January 2005 and March 2018 in this study. The baseline characteristics of the patients, response to S‐1 monotherapy, and adverse events (AEs) were investigated, retrospectively. Results A total of 68 male and 28 female patients (median age, 78 [range: 75–86] years) were analyzed. In elderly patients who were treated with S‐1 monotherapy as a subsequent‐line treatment, the objective response rate, disease control rate, median progression‐free survival (PFS), and overall survival (OS) were 8.3%, 43.8%, 3.4 months, and 9.6 months, respectively. Observed AEs included anorexia, anemia, nausea, fatigue, reduced platelet count, and skin hyperpigmentation. Treatment‐related death was observed in one patient because of pneumonitis. In patients who experienced no progressive disease, subsequent‐line S‐1 alone was associated with longer PFS and OS. Conclusions S‐1 monotherapy is effective and feasible as a subsequent‐line treatment in elderly patients who were previously treated for NSCLC, and it produces results. S‐1 monotherapy could be one of the treatment choices for elderly patients with previously treated NSCLC. |
topic |
Advanced non‐small cell lung cancer elderly patients S‐1 monotherapy subsequent‐line therapy |
url |
https://doi.org/10.1111/1759-7714.13622 |
work_keys_str_mv |
AT hisaoimai efficacyandsafetyofs1monotherapyinpreviouslytreatedelderlypatientsaged75yearswithnonsmallcelllungcanceraretrospectiveanalysis AT hiroyukiminemura efficacyandsafetyofs1monotherapyinpreviouslytreatedelderlypatientsaged75yearswithnonsmallcelllungcanceraretrospectiveanalysis AT takayukikishikawa efficacyandsafetyofs1monotherapyinpreviouslytreatedelderlypatientsaged75yearswithnonsmallcelllungcanceraretrospectiveanalysis AT yutakayamada efficacyandsafetyofs1monotherapyinpreviouslytreatedelderlypatientsaged75yearswithnonsmallcelllungcanceraretrospectiveanalysis AT kensukesuzuki efficacyandsafetyofs1monotherapyinpreviouslytreatedelderlypatientsaged75yearswithnonsmallcelllungcanceraretrospectiveanalysis AT yukihiroumeda efficacyandsafetyofs1monotherapyinpreviouslytreatedelderlypatientsaged75yearswithnonsmallcelllungcanceraretrospectiveanalysis AT satoshiwasamoto efficacyandsafetyofs1monotherapyinpreviouslytreatedelderlypatientsaged75yearswithnonsmallcelllungcanceraretrospectiveanalysis AT norimitsukasahara efficacyandsafetyofs1monotherapyinpreviouslytreatedelderlypatientsaged75yearswithnonsmallcelllungcanceraretrospectiveanalysis AT shinichiishihara efficacyandsafetyofs1monotherapyinpreviouslytreatedelderlypatientsaged75yearswithnonsmallcelllungcanceraretrospectiveanalysis AT ouyamaguchi efficacyandsafetyofs1monotherapyinpreviouslytreatedelderlypatientsaged75yearswithnonsmallcelllungcanceraretrospectiveanalysis AT ichironaruse efficacyandsafetyofs1monotherapyinpreviouslytreatedelderlypatientsaged75yearswithnonsmallcelllungcanceraretrospectiveanalysis AT junjiuchino efficacyandsafetyofs1monotherapyinpreviouslytreatedelderlypatientsaged75yearswithnonsmallcelllungcanceraretrospectiveanalysis AT keitamori efficacyandsafetyofs1monotherapyinpreviouslytreatedelderlypatientsaged75yearswithnonsmallcelllungcanceraretrospectiveanalysis AT kenyakanazawa efficacyandsafetyofs1monotherapyinpreviouslytreatedelderlypatientsaged75yearswithnonsmallcelllungcanceraretrospectiveanalysis AT yokoshibata efficacyandsafetyofs1monotherapyinpreviouslytreatedelderlypatientsaged75yearswithnonsmallcelllungcanceraretrospectiveanalysis AT takashikasai efficacyandsafetyofs1monotherapyinpreviouslytreatedelderlypatientsaged75yearswithnonsmallcelllungcanceraretrospectiveanalysis AT takayukikaburagi efficacyandsafetyofs1monotherapyinpreviouslytreatedelderlypatientsaged75yearswithnonsmallcelllungcanceraretrospectiveanalysis AT kyoichikaira efficacyandsafetyofs1monotherapyinpreviouslytreatedelderlypatientsaged75yearswithnonsmallcelllungcanceraretrospectiveanalysis AT koichiminato efficacyandsafetyofs1monotherapyinpreviouslytreatedelderlypatientsaged75yearswithnonsmallcelllungcanceraretrospectiveanalysis |
_version_ |
1724554199245520896 |